Logo image of ALZN

ALZAMEND NEURO INC (ALZN) Stock Fundamental Analysis

NASDAQ:ALZN - Nasdaq - US02262M5067 - Common Stock - Currency: USD

3.4  +0.11 (+3.34%)

After market: 3.4 0 (0%)

Fundamental Rating

2

ALZN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 562 industry peers in the Biotechnology industry. ALZN has a great financial health rating, but its profitability evaluates not so good. ALZN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALZN has reported negative net income.
In the past year ALZN has reported a negative cash flow from operations.
In the past 5 years ALZN always reported negative net income.
In the past 5 years ALZN always reported negative operating cash flow.
ALZN Yearly Net Income VS EBIT VS OCF VS FCFALZN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M

1.2 Ratios

With a Return On Assets value of -102.51%, ALZN is not doing good in the industry: 77.40% of the companies in the same industry are doing better.
The Return On Equity of ALZN (-124.08%) is worse than 60.68% of its industry peers.
Industry RankSector Rank
ROA -102.51%
ROE -124.08%
ROIC N/A
ROA(3y)-637.16%
ROA(5y)-465.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALZN Yearly ROA, ROE, ROICALZN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

ALZN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALZN Yearly Profit, Operating, Gross MarginsALZN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, ALZN has less shares outstanding
ALZN has less shares outstanding than it did 5 years ago.
ALZN has a worse debt/assets ratio than last year.
ALZN Yearly Shares OutstandingALZN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M
ALZN Yearly Total Debt VS Total AssetsALZN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 5M 10M

2.2 Solvency

ALZN has an Altman-Z score of -3.67. This is a bad value and indicates that ALZN is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -3.67, ALZN perfoms like the industry average, outperforming 46.98% of the companies in the same industry.
There is no outstanding debt for ALZN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.67
ROIC/WACCN/A
WACCN/A
ALZN Yearly LT Debt VS Equity VS FCFALZN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M 10M

2.3 Liquidity

A Current Ratio of 5.44 indicates that ALZN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.44, ALZN is in line with its industry, outperforming 58.72% of the companies in the same industry.
A Quick Ratio of 5.44 indicates that ALZN has no problem at all paying its short term obligations.
ALZN has a Quick ratio (5.44) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.44
Quick Ratio 5.44
ALZN Yearly Current Assets VS Current LiabilitesALZN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M

More info and screens

1

3. Growth

3.1 Past

ALZN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.88%, which is quite good.
EPS 1Y (TTM)18.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ALZN will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.79% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y94.04%
EPS Next 2Y39.82%
EPS Next 3Y25.36%
EPS Next 5Y14.79%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALZN Yearly Revenue VS EstimatesALZN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 100M 200M 300M
ALZN Yearly EPS VS EstimatesALZN Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALZN. In the last year negative earnings were reported.
Also next year ALZN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALZN Price Earnings VS Forward Price EarningsALZN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALZN Per share dataALZN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

A more expensive valuation may be justified as ALZN's earnings are expected to grow with 25.36% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.82%
EPS Next 3Y25.36%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALZN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALZAMEND NEURO INC

NASDAQ:ALZN (5/16/2025, 7:17:45 PM)

After market: 3.4 0 (0%)

3.4

+0.11 (+3.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-10 2025-03-10/amc
Earnings (Next)07-28 2025-07-28/bmo
Inst Owners2.09%
Inst Owner Change0%
Ins Owners3.75%
Ins Owner Change7.81%
Market Cap22.47M
Analysts80
Price Target20.4 (500%)
Short Float %N/A
Short Ratio0.98
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.74%
Min EPS beat(2)1.96%
Max EPS beat(2)47.53%
EPS beat(4)3
Avg EPS beat(4)-69.48%
Min EPS beat(4)-375.94%
Max EPS beat(4)48.51%
EPS beat(8)5
Avg EPS beat(8)-29.23%
EPS beat(12)7
Avg EPS beat(12)-18.93%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-37.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)16.67%
EPS NY rev (1m)0%
EPS NY rev (3m)4.17%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.51
P/tB 6.51
EV/EBITDA N/A
EPS(TTM)-15.17
EYN/A
EPS(NY)-1.24
Fwd EYN/A
FCF(TTM)-1.12
FCFYN/A
OCF(TTM)-1.11
OCFYN/A
SpS0
BVpS0.52
TBVpS0.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -102.51%
ROE -124.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-637.16%
ROA(5y)-465.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 177.52%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.44
Quick Ratio 5.44
Altman-Z -3.67
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95%
EPS Next Y94.04%
EPS Next 2Y39.82%
EPS Next 3Y25.36%
EPS Next 5Y14.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y66.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year57.5%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y11.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.44%
OCF growth 3YN/A
OCF growth 5YN/A